US2024024259A1PendingUtilityA1

Sphingosine pathway modulating compounds for the treatment of cancers

86
Assignee: ENZO BIOCHEM INCPriority: Jun 23, 2017Filed: Jul 28, 2023Published: Jan 25, 2024
Est. expiryJun 23, 2037(~10.9 yrs left)· nominal 20-yr term from priority
Inventors:Elazar RabbaniJames J. Donegan
A61K 31/137A61K 31/4245A61K 45/06A61K 31/135A61P 35/00A61P 35/02A61K 2300/00
86
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating prostate cancer in a mammalian subject, comprising the step of:
 administering to a mammalian subject in need of treatment for prostate cancer an effective amount of ozanimod or a pharmaceutically acceptable salt thereof.   
     
     
         2 . The method of  claim 1 , wherein the administering step comprises administering the hydrochloride salt of ozanimod to the mammalian subject. 
     
     
         3 . The method of  claim 1 , wherein the mammalian subject is a human. 
     
     
         4 . The method of  claim 3 , wherein the administering step comprises administering the hydrochloride salt of ozanimod to the mammalian subject.

Join the waitlist — get patent alerts

Track US2024024259A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.